SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Schrör, K.
Right arrow Articles by Mehta, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schrör, K.
Right arrow Articles by Mehta, J. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Cardiovascular Risk of Selective Cyclooxygenase-2 Inhibitors

Karsten Schrör, MD

Department of Pharmacology and Clinical Pharmacology, University of Düsseldorf, Germany

Paulette Mehta, MD

Department of Internal Medicine, University of Arkansas for Medical Sciences and the Central Arkansas Veterans Healthcare System, Little Rock, AR

Jawahar L. Mehta, MD, PhD

Department of Internal Medicine, University of Arkansas for Medical Sciences and the Central Arkansas Veterans Healthcare System, Little Rock, AR

Recently, cyclooxygenase-2 (COX-2) inhibitors (coxibs), a class of drugs intended to be painkillers, have created unprecedented controversy because of their cardiovascular risk profile. The controversy has affected the patients, health-care providers, the Food and Drug Administration, and the manufacturers of these agents alike. We summarize the mechanisms of actions of this class of agents, their cardiovascular risk as evident in multiple trials, the basis of their adverse risk profile, and our views on this issue.

Key Words: cyclooxygenase-2 inhibitors • myocardial infarction • familial adenomatous polyposis

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 10, No. 2, 95-101 (2005)
DOI: 10.1177/107424840501000203
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ther Adv Cardiovasc DisHome page
A. Aneja and M. E. Farkouh
Review: Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema?
Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 53 - 66.
[Abstract] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Hazra, R. K. Batra, H. H. Tai, S. Sharma, X. Cui, and S. M. Dubinett
Pioglitazone and Rosiglitazone Decrease Prostaglandin E2 in Non-Small-Cell Lung Cancer Cells by Up-Regulating 15-Hydroxyprostaglandin Dehydrogenase
Mol. Pharmacol., June 1, 2007; 71(6): 1715 - 1720.
[Abstract] [Full Text] [PDF]


Advertisement